secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0001104659-23-036860
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health reports 2022 prescription revenue up 179% to $11.9M; net loss narrows to $48.4M
--------------------------------------------------------------------------------

- Prescription product net revenue $11.9M for 2022, up 179% YoY from $4.3M in 2021.
- Net loss attributable to common shareholders $47.5M ($36.18 per share) vs $52.6M in 2021.
- Cash position approximately $15.3M as of March 24, 2023.
- Phase 3 OnTarget trial enrollment at ~80%; completion expected in Q2 2023.
- Orphan Drug Designation granted for crofelemer for MVID; IND submission planned Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000110465923036860/0001104659-23-036860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000110465923036860/tm2310147d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-036860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer